Dolutegravir

Drug Class

Integrase Strand Transfer Inhibitor (INSTI)

Mechanism of Action (MOA)

Inhibits HIV integrase → blocks integration of viral DNA into the host genome.

Clinical Notes

Backbone of first-line ART (usually with two NRTIs) — high resistance barrier, once daily. Weight gain; modest creatinine rise (↓ tubular secretion, not true renal injury); periconception neural-tube-defect signal now considered low risk.

Source

FDA label

Got a pharmacology lecture that covers Dolutegravir? Turn it into flashcards and board-style questions, free. Drop it on the home page